HERON THERAPEUTICS, INC. /DE/ Accounts Receivable, Allowance for Credit Loss
HERON THERAPEUTICS, INC. /DE/ (HRTX) had Accounts Receivable, Allowance for Credit Loss of $0 as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Assets
us-gaap:AllowanceForDoubtfulAccountsReceivable · last filed 2026-08-10
- 2026-06-30: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2026-03-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2025-12-31: Accounts Receivable, Allowance for Credit Loss $0.00.
- 2025-09-30: Accounts Receivable, Allowance for Credit Loss $0.00.
| Period end | Accounts Receivable, Allowance for Credit Loss |
|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-10 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-10 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-04 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-08 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-06 |
| 2024-12-31 | $0.00 10-Q · filed 2025-11-04 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-06 |
| 2023-12-31 | $0.00 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |